Clinical advances in pulmonary arterial hypertension: the year in review

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The purpose of this review is to summarize the last year of literature developments in the field of pulmonary arterial hypertension (PAH), with a focus on clinical research. RECENT FINDINGS: Pulmonary vascular research has expanded rapidly over the last decade, resulting in a change in the treatment strategy for PAH. Epidemiologic data from recent registries suggest that patients with PAH are increasing in age and comorbidities. In the modern treatment era, risk stratification for early mortality is increasingly used to guide clinicians in the choice of pulmonary vasodilator therapy. Risk-score calculators have been published and validated for PAH, currently in both the United States and Europe. In addition to increased comorbidities, pulmonary hypertension centers are encountering complicated management situations in these patients, such as pregnancy. Current data suggest that mortality for pregnant pulmonary hypertension patients remains high, although not as high as historical reports. Oral prostacyclin and prostacyclin agonist therapies are currently under investigation to aid in the management of these patients. SUMMARY: Despite treatment advances, mortality remains high for PAH patients. Careful evaluation and risk stratification will help guide the appropriate treatment for PAH patients. Additional therapies are on the horizon for the management of this progressive disease.

Original languageEnglish (US)
Pages (from-to)430-436
Number of pages7
JournalCurrent Opinion in Pulmonary Medicine
Volume19
Issue number5
DOIs
StatePublished - Sep 2013

Fingerprint

Pulmonary Hypertension
Epoprostenol
Therapeutics
Mortality
Comorbidity
Lung
Disease Management
Vasodilator Agents
Research
Blood Vessels
Registries
Pregnancy

Keywords

  • Pregnancy and pulmonary hypertension
  • Pulmonary arterial hypertension
  • Risk assessment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Clinical advances in pulmonary arterial hypertension : the year in review. / Bartolome, Sonja D.

In: Current Opinion in Pulmonary Medicine, Vol. 19, No. 5, 09.2013, p. 430-436.

Research output: Contribution to journalArticle

@article{a9b5e1f430014031b86bc92e1bf302e2,
title = "Clinical advances in pulmonary arterial hypertension: the year in review",
abstract = "PURPOSE OF REVIEW: The purpose of this review is to summarize the last year of literature developments in the field of pulmonary arterial hypertension (PAH), with a focus on clinical research. RECENT FINDINGS: Pulmonary vascular research has expanded rapidly over the last decade, resulting in a change in the treatment strategy for PAH. Epidemiologic data from recent registries suggest that patients with PAH are increasing in age and comorbidities. In the modern treatment era, risk stratification for early mortality is increasingly used to guide clinicians in the choice of pulmonary vasodilator therapy. Risk-score calculators have been published and validated for PAH, currently in both the United States and Europe. In addition to increased comorbidities, pulmonary hypertension centers are encountering complicated management situations in these patients, such as pregnancy. Current data suggest that mortality for pregnant pulmonary hypertension patients remains high, although not as high as historical reports. Oral prostacyclin and prostacyclin agonist therapies are currently under investigation to aid in the management of these patients. SUMMARY: Despite treatment advances, mortality remains high for PAH patients. Careful evaluation and risk stratification will help guide the appropriate treatment for PAH patients. Additional therapies are on the horizon for the management of this progressive disease.",
keywords = "Pregnancy and pulmonary hypertension, Pulmonary arterial hypertension, Risk assessment",
author = "Bartolome, {Sonja D.}",
year = "2013",
month = "9",
doi = "10.1097/MCP.0b013e3283644c8d",
language = "English (US)",
volume = "19",
pages = "430--436",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Clinical advances in pulmonary arterial hypertension

T2 - the year in review

AU - Bartolome, Sonja D.

PY - 2013/9

Y1 - 2013/9

N2 - PURPOSE OF REVIEW: The purpose of this review is to summarize the last year of literature developments in the field of pulmonary arterial hypertension (PAH), with a focus on clinical research. RECENT FINDINGS: Pulmonary vascular research has expanded rapidly over the last decade, resulting in a change in the treatment strategy for PAH. Epidemiologic data from recent registries suggest that patients with PAH are increasing in age and comorbidities. In the modern treatment era, risk stratification for early mortality is increasingly used to guide clinicians in the choice of pulmonary vasodilator therapy. Risk-score calculators have been published and validated for PAH, currently in both the United States and Europe. In addition to increased comorbidities, pulmonary hypertension centers are encountering complicated management situations in these patients, such as pregnancy. Current data suggest that mortality for pregnant pulmonary hypertension patients remains high, although not as high as historical reports. Oral prostacyclin and prostacyclin agonist therapies are currently under investigation to aid in the management of these patients. SUMMARY: Despite treatment advances, mortality remains high for PAH patients. Careful evaluation and risk stratification will help guide the appropriate treatment for PAH patients. Additional therapies are on the horizon for the management of this progressive disease.

AB - PURPOSE OF REVIEW: The purpose of this review is to summarize the last year of literature developments in the field of pulmonary arterial hypertension (PAH), with a focus on clinical research. RECENT FINDINGS: Pulmonary vascular research has expanded rapidly over the last decade, resulting in a change in the treatment strategy for PAH. Epidemiologic data from recent registries suggest that patients with PAH are increasing in age and comorbidities. In the modern treatment era, risk stratification for early mortality is increasingly used to guide clinicians in the choice of pulmonary vasodilator therapy. Risk-score calculators have been published and validated for PAH, currently in both the United States and Europe. In addition to increased comorbidities, pulmonary hypertension centers are encountering complicated management situations in these patients, such as pregnancy. Current data suggest that mortality for pregnant pulmonary hypertension patients remains high, although not as high as historical reports. Oral prostacyclin and prostacyclin agonist therapies are currently under investigation to aid in the management of these patients. SUMMARY: Despite treatment advances, mortality remains high for PAH patients. Careful evaluation and risk stratification will help guide the appropriate treatment for PAH patients. Additional therapies are on the horizon for the management of this progressive disease.

KW - Pregnancy and pulmonary hypertension

KW - Pulmonary arterial hypertension

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=84881638016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881638016&partnerID=8YFLogxK

U2 - 10.1097/MCP.0b013e3283644c8d

DO - 10.1097/MCP.0b013e3283644c8d

M3 - Article

C2 - 23907455

AN - SCOPUS:84881638016

VL - 19

SP - 430

EP - 436

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 5

ER -